Trials / Withdrawn
WithdrawnNCT05791474
ATI-2231 in Advanced Solid Tumor Malignancies
A Phase Ia Trial of ATI-2231 in Advanced Solid Tumor Malignancies
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this first-in-human study is to test ATI-2231 in advanced solid tumor malignancies with the goal of establishing the recommended Phase II dose of ATI-2231.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-2231 | Provided by Aclaris Therapeutics, Inc. |
Timeline
- Start date
- 2023-11-15
- Primary completion
- 2025-06-30
- Completion
- 2025-06-30
- First posted
- 2023-03-30
- Last updated
- 2023-11-29
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05791474. Inclusion in this directory is not an endorsement.